What is the relationship between Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) and red yeast rice (Monascus purpureus)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

There is no established direct interaction between red yeast rice supplements and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Red yeast rice, which contains naturally occurring statins (particularly monacolin K, similar to lovastatin), is generally not known to cause or worsen SIADH 1, 2, 3, 4, 5. However, patients with SIADH should exercise caution when taking any supplement, including red yeast rice. If you have SIADH and are considering taking red yeast rice, consult with your healthcare provider first. They may recommend starting with a low dose (typically 600-1200 mg daily) and monitoring your sodium levels regularly, especially during the first few weeks of supplementation.

Key Considerations

  • Red yeast rice supplements can have similar side effects to prescription statins, including muscle pain and liver enzyme elevations, but these are not typically related to fluid or electrolyte balance that would affect SIADH.
  • The primary management of SIADH involves fluid restriction, treating underlying causes, and sometimes medications like tolvaptan or demeclocycline that directly address the inappropriate water retention.
  • Any supplement should be considered secondary to these established treatments for SIADH.

Management of SIADH

  • According to the most recent study 4, the management of hyponatremia secondary to SIADH is largely dependent on the symptomatology of the patient.
  • Treatment options for SIADH include vaptans, which are vasopressin receptor antagonists targeted for the correction of euvolemic hyponatremia, such as that observed in SIADH.
  • It is essential to correct hyponatremia slowly (<10-12 mmol/l within the first 24 h, and <18 mmol/l within the first 48 h, respectively) to avoid osmotic myelinolysis 3.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.